Nucor earnings beat by $0.08, revenue fell short of estimates
Grigorios Siokas, the Chief Executive Officer of Cosmos Health Inc. (NASDAQ:COSM), has acquired 34,004 shares of the company’s common stock, according to a recent SEC filing. The transaction, executed on May 23, 2025, was part of a debt exchange agreement, where Siokas received shares at a price of $0.4475 per share. This acquisition represents a total value of $15,216. Following this transaction, Siokas holds a total of 6,158,884 shares in the company. With a market capitalization of $12.17 million, InvestingPro analysis suggests the stock is currently undervalued, while noting the company operates with a significant debt burden of $12.85 million. For deeper insights into insider transactions and company valuations, InvestingPro subscribers have access to 8 additional key tips about COSM’s financial health and prospects.
In other recent news, Cosmos Health Inc. has been granted an additional 180-day extension by the Nasdaq Stock Market to meet the minimum bid price requirement, with the new deadline set for November 3, 2025. The company is focused on regaining compliance by ensuring its stock price reaches or exceeds $1.00 per share for at least 10 consecutive business days. Additionally, Cosmos Health’s CEO, Greg Siokas, has increased his stake in the company by purchasing 1,466,764 common shares totaling $526,000, bringing his total ownership to over 5.5 million shares. Siokas has shown confidence in the company’s future, with a total investment of over $1.3 million in recent months.
Furthermore, Cosmos Health has secured a contract manufacturing agreement with Pharmex S.A. through its subsidiary, Cana Laboratories, to produce 300,000 bottles per year of the antiseptic drug AMBITASOL 1L over five years. This partnership is expected to boost revenue generation and strengthen the company’s manufacturing capabilities. In another strategic move, Cosmos Health has expanded into the Albanian market by launching its Sky Premium Life food supplements brand in partnership with Pharma Cell. An initial annual order valued at $300,000 has been secured, with plans to grow the collaboration further.
These developments are part of Cosmos Health’s broader strategy to enhance its global presence and revenue streams. The company’s recent activities, including the Nasdaq extension, CEO’s share purchase, manufacturing agreement, and market expansion, reflect its commitment to growth and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.